Want to join the conversation?
$GILD said it is stopping its combined Phase 2/3 clinical study of GS-5745 in patients with moderate to severe ulcerative colitis, or ulcers in the colon. The decision was taken after an interim analysis by the Data Monitoring Committee recommended that the study be terminated early due to meeting pre-specified futility and efficacy criteria.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?